HC Wainwright Reaffirms “Buy” Rating for Adlai Nortye (NASDAQ:ANL)

HC Wainwright restated their buy rating on shares of Adlai Nortye (NASDAQ:ANL) in a report issued on Monday morning,Benzinga reports. The firm currently has a $9.00 price objective on the stock.

Adlai Nortye Stock Up 3.8 %

Shares of NASDAQ ANL opened at $3.27 on Monday. Adlai Nortye has a 1-year low of $1.85 and a 1-year high of $17.48. The business’s fifty day moving average price is $2.16 and its two-hundred day moving average price is $4.52.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.